Preclinical studies in xenogeneic animal models of B-cell lymphoma have shown that CART19 cells manufactured from CD4 and CD8 TN and TCM cells have improved antitumor effect compared with those CART derived from more differentiated T-cell subsets (20, 72). Here, CD4 is linked to B-cell non-Hodgkin lymphoma.